A phase 2 pivotal trial of AB-PA01 to treat patients with P. aeruginosa infection
Latest Information Update: 20 Dec 2017
Price :
$35 *
At a glance
- Drugs AP PA01 (Primary)
- Indications Pseudomonal infections
- Focus Registrational; Therapeutic Use
- 20 Dec 2017 New trial record
- 14 Dec 2017 According to an AmpliPhi Biosciences media release, company plans to initiate the clinical trial in second half of 2018.